000281634 001__ 281634
000281634 005__ 20251103102758.0
000281634 0247_ $$2doi$$a10.1038/s41531-025-01161-2
000281634 0247_ $$2pmid$$apmid:41057346
000281634 037__ $$aDZNE-2025-01157
000281634 041__ $$aEnglish
000281634 082__ $$a610
000281634 1001_ $$aOphey, Anja$$b0
000281634 245__ $$aSubjective cognitive decline in individuals with isolated REM sleep behavior disorder.
000281634 260__ $$a[London]$$bSpringer Nature$$c2025
000281634 3367_ $$2DRIVER$$aarticle
000281634 3367_ $$2DataCite$$aOutput Types/Journal article
000281634 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1762161330_20025
000281634 3367_ $$2BibTeX$$aARTICLE
000281634 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281634 3367_ $$00$$2EndNote$$aJournal Article
000281634 520__ $$aSubjective cognitive decline (SCD) may constitute an early marker of mild cognitive impairment (MCI) in individuals with isolated REM sleep behavior disorder (iRBD). In this cross-sectional study, 80 individuals with iRBD were classified into iRBD with MCI (RBD.MCI), with SCD (RBD.SCD+), and without both (RBD.SCD-) based on neuropsychological testing and the Multi-SubCoDE questionnaire. The prevalence of SCD in iRBD was 36.3%, with predominance of the amnestic multi-domain SCD profile. RBD.SCD+ reported more severe depressive symptoms than RBD.SCD- and showed lower cognitive performance than RBD.SCD- in global cognition and attention & working memory. Magnetic resonance imaging analyses revealed lower grey matter volume in the left superior frontal gyrus for RBD.SCD+ than RBD.SCD-, which was associated with increased SCD-severity and lower global cognition. SCD without MCI in iRBD is associated with subtle cognitive deficits and structural brain changes. The prognostic value of SCD in iRBD should be further determined in longitudinal studies.
000281634 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281634 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281634 7001_ $$aRöttgen, Sinah$$b1
000281634 7001_ $$aDoppler, Christopher E J$$b2
000281634 7001_ $$aScharfenberg, Daniel$$b3
000281634 7001_ $$0P:(DE-2719)9003179$$aKufer, Konstantin$$b4$$udzne
000281634 7001_ $$aFarrher, Ezequiel$$b5
000281634 7001_ $$aFink, Gereon R$$b6
000281634 7001_ $$0P:(DE-2719)9003277$$aSommerauer, Michael$$b7$$udzne
000281634 7001_ $$aKalbe, Elke$$b8
000281634 773__ $$0PERI:(DE-600)2819218-7$$a10.1038/s41531-025-01161-2$$gVol. 11, no. 1, p. 287$$n1$$p287$$tnpj Parkinson's Disease$$v11$$x2373-8057$$y2025
000281634 8564_ $$uhttps://pub.dzne.de/record/281634/files/DZNE-2025-01157%20SUP.pdf
000281634 8564_ $$uhttps://pub.dzne.de/record/281634/files/DZNE-2025-01157.pdf$$yOpenAccess
000281634 8564_ $$uhttps://pub.dzne.de/record/281634/files/DZNE-2025-01157%20SUP.pdf?subformat=pdfa$$xpdfa
000281634 8564_ $$uhttps://pub.dzne.de/record/281634/files/DZNE-2025-01157.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281634 909CO $$ooai:pub.dzne.de:281634$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000281634 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003179$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000281634 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003277$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000281634 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281634 9141_ $$y2025
000281634 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000281634 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000281634 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-11
000281634 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281634 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ PARKINSONS DIS : 2022$$d2024-12-11
000281634 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:43:48Z
000281634 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:43:48Z
000281634 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000281634 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-11
000281634 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000281634 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281634 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:43:48Z
000281634 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-11
000281634 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ PARKINSONS DIS : 2022$$d2024-12-11
000281634 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000281634 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000281634 9201_ $$0I:(DE-2719)1011302$$kAG Wüllner$$lBiomarker Parkinson's Disease$$x0
000281634 9201_ $$0I:(DE-2719)1013020$$kAG Petzold$$lVascular Neurology$$x1
000281634 980__ $$ajournal
000281634 980__ $$aVDB
000281634 980__ $$aUNRESTRICTED
000281634 980__ $$aI:(DE-2719)1011302
000281634 980__ $$aI:(DE-2719)1013020
000281634 9801_ $$aFullTexts